Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo

Blood Cancer Journal

Volumn 2, Issue 4, 2012, Pages

  Kiziltepe, T ^a,b   Ashley, J D ^a   Stefanick, J F ^a   Qi, Y M ^a   Alves, N J ^a   Handlogten, M W ^a   Suckow, M A ^b   Navari, R M ^c   Bilgicer, B ^a,b  

^a University of Notre Dame   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell adhesion mediated drug resistance; Drug delivery; Multiple myeloma; Nanoparticle; Selective targeting; VLA 4

Indexed keywords

DOUBLE STRANDED DNA; DOXORUBICIN; FIBRONECTIN; HYDRAZONE DERIVATIVE; NANOPARTICLE; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG ACCUMULATION; DRUG EFFICACY; FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MICELLE; MOUSE; MULTIPLE MYELOMA; NANOENGINEERING; NONHUMAN; PARTICLE SIZE; STROMA CELL; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84864046050     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.10     Document Type: Article

References (47)

1. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011; 29: 1916-1923.
2. Hideshima T, Richardson P, Anderson K. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003; 194: 164-176.
3. Sanz-Rodriguez F, Teixido J. VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma 2001; 41: 239-245.
4. Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
5. Schmidmaier R, Baumann P. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem 2008; 15: 978-990.
6. Vincent A, Cawley J, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996; 87: 4780-4788.
7. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158-1165.
8. Carpenter RD, Andrei M, Aina OH, Lau EY, Lightstone FC, Liu R et al. Selectively targeting T-and B-cell lymphomas: A benzothiazole antagonist of alpha(4)beta(1) integrin. J Med Chem 2009; 52: 14-19.
9. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231-242.
10. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 2011; 155: 438-448.
11. Olson D, Burkly L, Leone D, Dolinski B, Lobb R. Anti-alpha 4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005; 4: 91-99.
12. US Department of Health and Human Services. National Institute of Health & National Cancer Institute. A strategic initiative to transform clinical oncology and basic research through the directed application of nanotechnology. Available at http://nano.cancer.gov/about-alliance/cancer-nanotechnology-plan, 2004.
13. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 2000; 65: 271-284.
14. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005; 2: 369-381.
15. Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol 2011; 94: 334-343.
16. Kumar S, Witzig T, Timm M, Haug J, Wellik L, Kimlinger T et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104: 1159-1165.
17. Singh Bhatti S, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 2006; 81: 649-656.
18. Hussein M, Anderson K. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol 2004; 31: 147-160.
19. Chanan-Khan AA, Lee K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: Rationale and clinical experience. Clin Lymphoma Myeloma 2007; 7: S163-S169.
20. Ning Y, He K, Dagher R, Sridhara R, Farrell AT, Justice R et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology 2007; 21: 1503-1508.
21. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med 2009; 234: 123-131.
22. Sawant RR, Torchilin VP. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol 2010; 27: 232-246.
23. Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L et al. JS-K, a GSTactivated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007; 110: 709-718.
24. Yang H, Meng Z, Zhang C, Zhang P, Wang Q. Establishing a new rat model of central venous sinus thrombosis and analyzing its pathophysiological and apoptotic changes. J Neurosci Methods 2011; 203: 130-135.
25. Laginha K, Verwoert S, Charrois G, Allen T. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005; 11: 6944-6949.
26. Lin K, Castro A. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol 1998; 2: 453-457.
27. Singh J, Adams S, Carter M, Cuervo H, Lee W, Lobb R et al. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr Top Med Chem 2004; 4: 1497-1507.
28. Jackson D, Quan C, Artis D, Rawson T, Blackburn B, Struble M et al. Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents. J Med Chem 1997; 40: 3359-3368.
29. Ashok B, Arleth L, Hjelm R, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation. J Pharm Sci 2004; 93: 2476-2487.
30. Johnsson M, Hansson P, Edwards K. Spherical micelles and other self-assembled structures in dilute aqueous mixtures of poly(ethylene glycol) lipids. J Phys Chem B 2001; 105: 8420-8430.
31. Lukyanov A, Gao Z, Mazzola L, Torchilin V. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res 2002; 19: 1424-1429.
32. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009; 71: 409-419.
33. Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res 2007; 24: 1-16.
34. Bae Y, Alani AWG, Rockich NC, Lai TSZC, Kwon GS. Mixed pH-sensitive polymeric micelles for combination drug delivery. Pharm Res 2010; 27: 2421-2432.
35. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med 2010; 6: 714-729.
36. Richardson D, Johnson S. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 1997; 11: 201-223.
37. Burma S, Chen B, Murphy M, Kurimasa A, Chen D. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001; 276: 42462-42467.
38. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008; 6: 278-281.
39. Giri S, Al-Bayati M, Schelegle E, Mohr F, Margolin S, Du X. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 2004; 53: 141-150.
40. Burke J, Laucius J, Brodovsky H, Soriano R. Doxorubicin Hydrochloride-associated renal-failure. Arch Intern Med 1977; 137: 385-388.
41. Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 3: 421-437.
42. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68: 6652-6660.
43. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009; 3: 2505-2514.
44. Aina O, Sroka T, Chen M, Lam K. Therapeutic cancer targeting peptides. Biopolymers 2002; 66: 184-199.
45. Owen RM, Carlson CB, Xu JW, Mowery P, Fasella E, Kiessling LL. Bifunctional ligands that target cells displaying the alpha(v)beta(3) integrin. Chem BioChem 2007; 8: 68-82.
46. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Edit 1998; 37: 2755-2794.
47. Mitsiades CS, Anderson KC, Carrasco DR. Mouse models of human myeloma. Hematol Oncol Clin North Am 2007; 21: 1051.